Clinical Trial

To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat plaque psoriasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-28.
Status change: Active, Not Recruiting → Completed 2026-04-14
Trial Details
NCT Number NCT07008547
Lead Sponsor SPH-BIOCAD (HK) Limited
Conditions Plaque Psoriasis
Enrollment 202 participants
Start Date 2024-07-30
Primary Completion 2025-03-28 (estimated)
Study Completion 2025-06-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-15